This article is part of the supplement: Lupus 2012: New targets, new approaches

Meeting abstract

Which lupus trial endpoints best reflect clinical judgment or biomarker improvement?

A Thanou, M Munroe, S Kamp, F Carthen, JA James and JT Merrill*

  • * Corresponding author: JT Merrill

Arthritis Research & Therapy 2012, 14(Suppl 3):A47 doi:10.1186/ar3981

Accesses  

  • Last 30 days: 50 accesses
  • Last 365 days: 285 accesses
  • All time: 285 accesses

Cited by

Google Scholar: View citations